

## **CARTER BLOODCARE SERVICE MANUAL**

Department of Health and Human Services, Food and Drug Administration

- FDA Biologics License number 1274

Centers for Medicare & Medicaid Services (CMS)

- CLIA certificate number 45D0486046 (Bedford)

Foundation for the Accreditation of Cellular Therapy

- (FACT does not provide accreditation numbers)

If you require a copy of any of these licenses or if you require a different license not listed above, please contact Hospital Relations.

## 1.5 Department Descriptions and Contact Directory

Carter BloodCare  
2205 Highway 121  
Bedford, TX 76021

Carter BloodCare  
815 South Baxter Avenue  
Tyler, TX 75701

1-800-DONATE4  
[carterbloodcare.org](http://carterbloodcare.org)

### Clinical Services

*Peripheral blood stem cell collection, therapeutic apheresis procedures including plasmapheresis, cytoreduction and red cell exchange, photopheresis, lymphocyte collections, and granulocyte collections*

Main number \_\_\_\_\_ (972) 788-0650  
Fax number \_\_\_\_\_ (972) 661-9409

Granulocyte Orders Pager \_\_\_\_\_ (817) 482-9446

### Distribution/Hospital Services

*Order, delivery and inventory inquiries, inventory management and consultation, autologous and directed unit deliveries*

#### North Texas

Main number \_\_\_\_\_ (817) 412-5700  
Fax number \_\_\_\_\_ (817) 412-5729

Howard Jenkins \_\_\_\_\_ (817) 412-5714  
Shift Operations Manager [hjenkins@carterbloodcare.org](mailto:hjenkins@carterbloodcare.org)

Doug Heath \_\_\_\_\_ (817) 412-5715  
Director of Laboratory Operations [dheath@carterbloodcare.org](mailto:dheath@carterbloodcare.org)

#### Central Texas

Main number \_\_\_\_\_ (254) 297-4100  
Fax number \_\_\_\_\_ (254) 399-6391

Marla Boren \_\_\_\_\_ (903) 363-0433  
Manager of Site Operations [mboren@carterbloodcare.org](mailto:mboren@carterbloodcare.org)

Josey Keep \_\_\_\_\_ (254) 297-4101  
Shift Supervisor [jkeep@carterbloodcare.org](mailto:jkeep@carterbloodcare.org)

## CARTER BLOODCARE SERVICE MANUAL

### East Texas

Main number \_\_\_\_\_ (903) 363-0404

Fax number \_\_\_\_\_ (903) 363-0483

Marla Boren \_\_\_\_\_ (903) 363-0433

Manager of Site Operations [mboren@carterbloodcare.org](mailto:mboren@carterbloodcare.org)

Jared Jordan \_\_\_\_\_ (903) 363-0403

Operations Coordinator [jjordan@carterbloodcare.org](mailto:jjordan@carterbloodcare.org)

### Donor Notification

*Donor notification of significant test results, transfusion-transmitted disease investigations, donor re-entry*

Main number \_\_\_\_\_ (817) 412-5603

Fax number \_\_\_\_\_ (817) 412-5609

Pat Davenport, MT(ASCP)SBB \_\_\_\_\_ (817) 412-5604

Manager of Special Donor Services [pdavenport@carterbloodcare.org](mailto:pdavenport@carterbloodcare.org)

### Donor Recruitment

*Blood drive recruitment and scheduling*

Rhonda Cantrell \_\_\_\_\_ (817) 412-5384

Administrative Assistant [rcantrell@carterbloodcare.org](mailto:rcantrell@carterbloodcare.org)

Todd Abner \_\_\_\_\_ (817) 412-5385

Director of Mobile Recruitment [tabner@carterbloodcare.org](mailto:tabner@carterbloodcare.org)

### East Texas

Jacquelyn Decker \_\_\_\_\_ (903) 363-0432

Manager of Operations and Field Recruitment [jsdecker@carterbloodcare.org](mailto:jsdecker@carterbloodcare.org)

### Finance and Billing

Fax number \_\_\_\_\_ (817) 412-5136

#### Main contact for invoice or billing

Cheryl Stark

Accounts Receivable Coordinator \_\_\_\_\_ (817) 412-5123

[cstark@carterbloodcare.org](mailto:cstark@carterbloodcare.org)

Nancy Perez \_\_\_\_\_ (817) 412-5121

Chief Financial Officer [nperez@carterbloodcare.org](mailto:nperez@carterbloodcare.org)

## CARTER BLOODCARE SERVICE MANUAL

Scott Gastorf \_\_\_\_\_ (817) 412-5139  
Director of Finance [sgastorf@carterbloodcare.org](mailto:sgastorf@carterbloodcare.org)

### Hospital Relations

*Customer service related, iWeBB activities, Customer Incident reporting and tracking, educational in-services, transfusion service mock audits, Service Manual information and updates*

Veronica Moore, MBA, MT(ASCP) \_\_\_\_\_ (817) 412-5328  
Director of Hospital Relations Cell \_\_\_\_\_ (817) 822-8956  
[vmoore@carterbloodcare.org](mailto:vmoore@carterbloodcare.org)

Judy Thornburg, MLT(ASCP) \_\_\_\_\_ (817) 412-5719  
Hospital Relations Advocate Cell \_\_\_\_\_ (817) 343-3324  
[jthornburg@carterbloodcare.org](mailto:jthornburg@carterbloodcare.org)

Andrea Sign \_\_\_\_\_ (817) 412-5825  
Manager of Client Relations Cell \_\_\_\_\_ (817) 706-2447  
[asign@carterbloodcare.org](mailto:asign@carterbloodcare.org)

Note: Inquiries can be directed to [hospitalrelations@carterbloodcare.org](mailto:hospitalrelations@carterbloodcare.org)

### Medical Services

*Medical consultation*

Main number \_\_\_\_\_ (817) 412-5104  
Fax number \_\_\_\_\_ (817) 412-5117

Laurie Sutor, M.D. \_\_\_\_\_ (817) 412-5601  
Vice President Medical & Technical Services [lsutor@carterbloodcare.org](mailto:lsutor@carterbloodcare.org)

Geeta Paranjape, M.D. \_\_\_\_\_ (817) 412-5612  
Medical Director of Clinical Services [gparanjape@carterbloodcare.org](mailto:gparanjape@carterbloodcare.org)

Todd Nishimoto, M.D. \_\_\_\_\_ (817) 412-5236  
Medical Director of Clinical Apheresis [tnishimoto@carterbloodcare.org](mailto:tnishimoto@carterbloodcare.org)

William Crews, M.D. \_\_\_\_\_ (817) 412-5611  
Medical Director of Laboratory Services [wcrews@carterbloodcare.org](mailto:wcrews@carterbloodcare.org)

Lesley Kresie, M.D. \_\_\_\_\_ (817) 412-5610  
Medical Director of HLA Services [lkresie@carterbloodcare.org](mailto:lkresie@carterbloodcare.org)

## CARTER BLOODCARE SERVICE MANUAL

### Quality Assurance

Lookback, product recalls, regulatory consultation

Main number \_\_\_\_\_ (817) 412-5580  
Fax number \_\_\_\_\_ (817) 412-5659

Nancy Arnett \_\_\_\_\_ (817) 412-5577  
Director of Quality Assurance [narnett@carterbloodcare.org](mailto:narnett@carterbloodcare.org)

### East Texas

Main number \_\_\_\_\_ (903) 363-0419  
Fax number \_\_\_\_\_ (903) 363-0467

Polly Wynn \_\_\_\_\_ (903) 363-0419  
Manager of Quality Assurance [pwynn@carterbloodcare.org](mailto:pwynn@carterbloodcare.org)

### Immunoematology Reference Laboratory and Transfusion Services

*Transfusion accounts, sample pick-up and receipt, transfusion inquiries, antibody identification, antigen screening, HLA platelet orders, platelet antibody orders, transfusion reaction notification, general transfusion and MD consultation, and flow cytometry*

Main number \_\_\_\_\_ (817) 412-5740  
Fax number \_\_\_\_\_ (817) 412-5749

Sandy Wortman, MT(ASCP),SBB \_\_\_\_\_ (817) 412-5271  
Director of Reference and Transfusion [swortman@carterbloodcare.org](mailto:swortman@carterbloodcare.org)

Pamela Boyd, MT(ASCP),BB \_\_\_\_\_ (817) 412-5229  
Manager Reference and Transfusion [pboyd@carterbloodcare.org](mailto:pboyd@carterbloodcare.org)

Mike Newhouse, MT(ASCP),SBB \_\_\_\_\_ (972) 566-4910  
Manager Reference and Transfusion [mnewhouse@carterbloodcare.org](mailto:mnewhouse@carterbloodcare.org)

Marie Becerra, MT(ASCP) \_\_\_\_\_ (817) 702-2040  
Manager Reference and Transfusion [mbecerra@carterbloodcare.org](mailto:mbecerra@carterbloodcare.org)

### Molecular Services (AABB Accredited)

*Donor and patient RBC genotyping/ predicted phenotype testing; discrepancy resolution and 24/7 consultation services.*

## CARTER BLOODCARE SERVICE MANUAL

Main number \_\_\_\_\_ (817) 412-5740  
Fax number \_\_\_\_\_ (817) 412-5749

### Preventative Maintenance Services

*Pipette calibration and maintenance; digital timer calibration; and thermometer standardization.*

Main number \_\_\_\_\_ (903) 363-0469  
Fax number \_\_\_\_\_ (903) 363-0451

### Special Donations

*Autologous, directed and therapeutic unit scheduling, tracking and consultation.*

**NOTE:** For delivery requests, please refer to Distribution/Hospital Services

Main number \_\_\_\_\_ (817) 412-5308  
Toll free number \_\_\_\_\_ 1(866) 525-3378  
Fax number \_\_\_\_\_ (817) 412-5318

### Stem Cell Laboratory Services

*Peripheral blood stem cell collections, assistance with surgical harvest of bone marrow, processing, cryopreservation, storage, thawing and infusion of stem cells, CD34 selection*

Main number \_\_\_\_\_ (817) 412-5743  
Fax number \_\_\_\_\_ (817) 412-5746

Vincent Zost, MT(ASCP),SBB \_\_\_\_\_ (817) 412-5743  
Stem Cell Laboratory Manager [vzost@carterbloodcare.org](mailto:vzost@carterbloodcare.org)

### Component Production and Testing and Labeling

*Viral marker testing, viral marker test results, labeling and release of blood components*

Main number \_\_\_\_\_ (817) 412-5731  
Fax number \_\_\_\_\_ (817) 412-5748

Regina Collier, MT (AMT) \_\_\_\_\_ (817) 412-5733  
Component Production & Testing and Labeling Manager [rcollier@carterbloodcare.org](mailto:rcollier@carterbloodcare.org)

## CARTER BLOODCARE SERVICE MANUAL

### Administration

Main number \_\_\_\_\_ (817) 412-5000

Fax number \_\_\_\_\_ (817) 412-5992

Merlyn H. Sayers, MB, BCh, PhD \_\_\_\_\_ (817) 412-5101

Chief Executive Officer [msayers@carterbloodcare.org](mailto:msayers@carterbloodcare.org)

Shankar Goudar \_\_\_\_\_ (817) 412-5344

Vice President of Corporate Services [goudar@carterbloodcare.org](mailto:goudar@carterbloodcare.org)

B.J. Smith \_\_\_\_\_ (817) 412-5158

Vice President of Regional Operations & Business Development

[bjsmith@carterbloodcare.org](mailto:bjsmith@carterbloodcare.org)

Human Resources Job Hotline \_\_\_\_\_ (817) 412-5150

### East Texas

Main number \_\_\_\_\_ (903) 363-0400

Carla Beck \_\_\_\_\_ (903) 363-0443

Director of East Texas Operations [cbeck@carterbloodcare.org](mailto:cbeck@carterbloodcare.org)

### Central Texas

Main Number \_\_\_\_\_ (254) 297-4000

Vickie Carpenter \_\_\_\_\_ (254) 297-4004


Manager of Recruitment Operations [vcarpenter@carterbloodcare.org](mailto:vcarpenter@carterbloodcare.org)

## 1.6 Forms

- Organizational Charts

# Carter BloodCare Organization Chart

*Dotted line from QA Director indicates Quality Assurance oversight*





**Legend**  
 Solid Lines: Direct Reporting  
 Dashed Lines: Secondary Reporting

**Dr. Merlyn Sayers**  
 Chief Executive Officer

**Nancy Arnett**  
 Quality Assurance  
 Director

**B.J. Smith**  
 VP of Regional Operations  
 and Business Development

Quality has oversight for ALL CBC  
 regulatory departments

**Polly Wynn**  
 Manager, Tyler  
 Quality Assurance

**Carter BloodCare**  
 Corporate Operations  
 Bedford  
 Refer to separate organizational chart

**Carla Beck**  
 Director of Operations

**Sandy Wortman, Director**  
 Reference & Transfusion

**Melonye Rodgers - Manager**  
 • Mobile Collections  
 • Training/NEO

**Dr. Lesley Kresie**  
 Medical Director of HLA  
 Services

**Bridgitte O'Daniel**  
 Operations Coordinator  
 • Donor Center Collections

**Shawn Benton**  
 IS Operations Manager

**Jeff Reed**  
 IT Support II Specialist

**Jan Decker**  
 Supervisor Administrative  
 Services

**Terrie Henderson**  
 Director Human  
 Resources

**Brandi Kile**  
 Human Resources  
 Generalist

**Marla Boren, Manager**  
 • Distribution – East and  
 Central Texas  
 • Component Processing  
 • Radiation Safety Officer

**Todd Abner**  
 Director of Mobile  
 Recruitment

**Jacquelyn Decker**  
 Manager Operations

**Rick Thornburg**  
 Hematology Manager

**Denise Fyffe**  
 Hematology Assistant  
 Manager

## CARTER BLOODCARE SERVICE MANUAL

((see example form in this section) will be included for your facility to complete and return by fax to the Quality Assurance department. Each facility should determine what steps to take when a recalled blood component has been transfused.

For additional information regarding Recall/Market Withdrawal notices, please contact the Quality Assurance department.

### **2.4 Quality Assurance Consultation Services**

The Carter BloodCare Quality Assurance department staff is available to provide information to answer questions on FDA and AABB requirements for Transfusion Services. Additionally, the Quality Assurance department can assist you in the development of your Quality Plan.

Carter BloodCare license information and component quality control summary data are available for your review upon request.

Please contact the Quality Assurance department or the Hospital Relations department for more information.

### **2.5 Forms**

QAF402.01A, Quarantine Request Facsimile  
QAF402.01B, Quarantine Release Request Facsimile  
QAF403.01, Suspected Component Contamination Notification  
QAF601.01A, Component Recall/Market Withdrawal  
QAF601.01C, Component Market/Withdrawal Notification  
QAF601.01.01, Notice of Increased Risk of Transfusion-Transmitted Malaria  
QAF602.01, Consignee Notification Record  
QAF602.01.01, Reactive Non-Discriminate Multiplex HIV/HCV Assay Notification  
QAF602.03.01B, Creutzfeldt-Jakob Disease (CJD) Notice



# REACTIVE NON-DISCRIMINATE MULTIPLEX HIV-1/HCV ASSAY NOTIFICATION

EMPLOYEE ID: \_\_\_\_\_

DATE: \_\_\_\_\_

Q.A. FILE NUMBER: \_\_\_\_\_

FACILITY NAME: \_\_\_\_\_

*This is a request to retrieve the disposition of the unit(s) listed below. If the component(s) is in stock, place it in quarantine.*

*Contact Distribution and Product Management personnel at the following Carter BloodCare location for pick-up:*

North/Central Texas 817-412-5700

East Texas 903-363-0404

The donor of the following unit(s) has subsequently tested reactive on a Multiplex (individual donor) Nucleic Acid Test (NAT) for HIV-1 and HCV. The unit(s) listed below was negative for all infectious disease testing.

### Initial Test Results:

Multiplex NAT HIV-1 and HCV = Reactive

Anti-HCV EIA = Non-Reactive

Anti-HIV-1/2 EIA = Non-Reactive

### Additional Test Results

NAT HCV RNA \_\_\_\_\_

NAT HIV-1 RNA \_\_\_\_\_

If discriminatory for HIV-1 or HCV, notification will become a lookback. Further notification will be performed on form QAF602.01 Consignee Notification Record.

**Lookback:**  Recipient Notification **REQUIRED** for HIV and HCV  
Date of Last Negative Donation: \_\_\_\_\_ Date of Positive Donation: \_\_\_\_\_ Reported By: \_\_\_\_\_ Date: \_\_\_\_\_

*Please complete the form and fax it back to the following Carter BloodCare Quality Assurance location:*

North/Central Texas 817-412-5659

East Texas 903-363-0467

| DIN/BUN | Product Code | Product Type | ABO/Rh | Shipment # | Ship Date | Final Disposition | Date of Disposition |
|---------|--------------|--------------|--------|------------|-----------|-------------------|---------------------|
|         |              |              |        |            |           |                   |                     |
|         |              |              |        |            |           |                   |                     |
|         |              |              |        |            |           |                   |                     |

**Disposition:** T = Transfused D = Discarded/Outdated R = Returned to Carter BloodCare RNA = Records Not Available

Other (Specify): \_\_\_\_\_

Questions regarding this notification should be directed to the following Carter BloodCare Quality Assurance location:

North/Central Texas 817-412-5580

East Texas 903-363-0419

\_\_\_\_\_  
Name ([print] person completing form)

\_\_\_\_\_  
Date

\_\_\_\_\_  
Facility

\_\_\_\_\_  
Signature (person completing form)

\_\_\_\_\_  
Title

## CARTER BLOODCARE SERVICE MANUAL

emergency/disaster situation. Carter BloodCare will immediately make the necessary contacts with the local, state and/or governmental agencies, coordinate with local hospitals that might be affected and contact all internal Directors/designees to insure a **coordinated direction of response**.

**The facility in Bedford is designed to be self-sufficient to help maintain operations.** The facility is equipped with the following **redundant systems**: air conditioning and heating, generated power, specially designed refrigeration equipment for blood storage, uninterrupted power sources, and **duplicated processes for many of our critical operations**. With the exception of a catastrophic disaster, directly to the campus, Carter BloodCare's facility in Bedford will be operational.

### 3.2 Blood Service Agreement Statement

#### ***Contact Information:***

Hospital Relations  
Carter BloodCare  
2205 Highway 121  
Bedford, TX 76021  
Phone: (817) 412-5328  
(817) 412-5825  
(817) 412-5719  
Fax: (817) 412-5991

Carter BloodCare is required by regulating agencies to have a signed, current Blood Service Agreement on file before providing blood products and services to any facility. To initiate a Blood Service Agreement or to obtain a copy of your current Blood Service Agreement, please contact the Hospital Relations department. It is highly recommended that you maintain a copy of your current Blood Service Agreement on file.

### 3.3 Finance and Billing Policies

#### ***Contact Information:***

Accounting & Finance  
Carter BloodCare  
2205 Highway 121  
Bedford, TX 76021  
Phone: (817) 412-5123 or (817) 412-5139  
Fax: (817) 412-5136

Phone: (817) 412-5328 – Hospital Relations Department  
(817) 412-5825  
(817) 412-5719

## 4.0 REPORTING SUSPECTED TRANSFUSION COMPLICATIONS

### 4.1 REPORTING ADVERSE REACTIONS

#### **Contact Information:**

Immunohematology Reference and Transfusion Services Laboratory  
Carter BloodCare  
2205 Highway 121  
Bedford, TX 76021  
Phone: (817) 412-5740  
Fax: (817) 412-5749

#### **4.1.1 Definition**

The term “**transfusion reaction**” refers to a group of complications that may arise during or after the administration of blood components to a patient. The severity of these complications may range from mild discomfort to serious life-threatening hemolytic or septic reactions. Fatal transfusion reactions can occur in spite of technical perfection.

#### **4.1.2 Types of Adverse Transfusion Reactions**

##### **Allergic Reactions**

Mild allergic reactions may occur in 1-3% of transfused recipients. These reactions are usually caused by antibodies (IgE) in the recipient directed against foreign proteins in the transfused plasma. Mild symptoms of allergic reaction include urticaria (hives), rash and itching. Such reactions may be treated with an antihistamine medication and the transfusion resumed when symptoms subside. More serious signs or symptoms are swelling of the lips, face or tongue, itching of the throat, or difficulty breathing. These symptoms should cause immediate discontinuation of the transfusion and close attention to avoid anaphylactic shock. Units of blood involved in reactions with allergic symptoms other than mild skin reactions should not be used for further transfusion.

##### **Febrile Non-hemolytic Reactions**

Febrile non-hemolytic reactions are defined by a rise in body temperature of  $\geq 1^{\circ}\text{C}$  with no other known cause for fever. These reactions may occur in 0.5 – 1.5% of transfusion recipients and may be more common in frequently transfused patients. These reactions are usually caused by antibodies of the recipient directed against white blood cell antigens in the transfused blood component. These reactions are seldom dangerous,



# REFERENCE AND TRANSFUSION SERVICES

## TRANSFUSION REACTION INVESTIGATION

### PRELIMINARY REPORT

|  |   |
|--|---|
| Patient Name: _____<br>ID Number: _____<br>Requesting Facility: _____<br>Ordering Physician: _____ | Sample Collection Date & Source: _____<br>Date Request Received: _____<br>Diagnosis: _____<br>Patient Date of Birth & Gender: _____ |
|--|---|

| UNIT INFORMATION          |  |
|---------------------------|--|
| Unit Number: _____        | Date/Time of Transfusion Reaction: _____ |
| Component Involved: _____ | Amount Transfused: _____ ml              |

| REACTION DETAILS         |                |                          |                           |
|--------------------------|----------------|--------------------------|---------------------------|
| <input type="checkbox"/> | Chills present | <input type="checkbox"/> | Nausea/Vomiting           |
| <input type="checkbox"/> | Fever          | <input type="checkbox"/> | Urticaria / Hives / Rash  |
| <input type="checkbox"/> | Dyspnea        | <input type="checkbox"/> | Hematuria                 |
| <input type="checkbox"/> | Shock          | <input type="checkbox"/> | Back or Chest Pain        |
| <input type="checkbox"/> | Jaundice       |                          |                           |
|                          |                |                          | <b>Other listed below</b> |
| _____                    |                |                          |                           |
| _____                    |                |                          |                           |
| _____                    |                |                          |                           |

| INVESTIGATION FINDINGS  |   |  |  |
|---|---|--|--|
| <input type="checkbox"/> Clerical checks were performed and found acceptable<br><input type="checkbox"/> Visual inspection of the pre- and post-sample was normal<br><input type="checkbox"/> Pre and Post transfusion sample testing resulted in no discrepancies<br><input type="checkbox"/> There is no evidence of red cell incompatibility | <input type="checkbox"/> Discrepancy noted in Clerical/Visual paper work check<br><input type="checkbox"/> Hemolysis present in post transfusion sample<br><input type="checkbox"/> Discrepancy noted in sample testing<br><input type="checkbox"/> Evidence of red cell incompatibility<br><input type="checkbox"/> * Gram stain and culture results pending |  |  |
| Patient Pre-transfusion DAT: POLY <input type="checkbox"/> IGG <input type="checkbox"/> C3 <input type="checkbox"/><br>Patient Post-transfusion DAT: POLY <input type="checkbox"/> IGG <input type="checkbox"/> C3 <input type="checkbox"/>   |   |  |  |

| REACTION CLASSIFICATION   |  |
|---|--|
| <input checked="" type="checkbox"/> * Pending Medical Director Review |  |

| RECOMMENDATIONS and COMMENTS  |  |
|---|--|
| <input checked="" type="checkbox"/> * Pending Medical Director Review |  |
| COMMENTS: _____   |  |
| _____   |  |
| _____   |  |
| _____   |  |

|                       |             |
|-----------------------|-------------|
| Results called to:    | Date / Time |
| Testing performed by: | Date / Time |



# REFERENCE AND TRANSFUSION SERVICES

## TRANSFUSION REACTION INVESTIGATION

### FINAL REPORT

|  |   |
|--|---|
| Patient Name: _____<br>ID Number: _____<br>Requesting Facility: _____<br>Ordering Physician: _____ | Sample Collection Date & Source: _____<br>Date Request Received: _____<br>Diagnosis: _____<br>Patient Date of Birth & Gender: _____ |
|--|---|

| UNIT INFORMATION          |  |
|---------------------------|--|
| Unit Number: _____        | Date/Time of Transfusion Reaction: _____ |
| Component Involved: _____ | Amount Transfused: _____ ml              |

| REACTION DETAILS         |                          |                          |                           |
|--------------------------|--------------------------|--------------------------|---------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <b>Other listed below</b> |
| <input type="checkbox"/> | Chills present           | <input type="checkbox"/> | Nausea/Vomiting           |
| <input type="checkbox"/> | Fever                    | <input type="checkbox"/> | Urticaria / Hives / Rash  |
| <input type="checkbox"/> | Dyspnea                  | <input type="checkbox"/> | Hematuria                 |
| <input type="checkbox"/> | Shock                    | <input type="checkbox"/> | Back or Chest Pain        |
| <input type="checkbox"/> | Jaundice                 |                          |                           |

| INVESTIGATION FINDINGS                                      |  |                              |   |
|---|--|------------------------------|---|
| <input type="checkbox"/>                                    | Clerical checks were performed and found acceptable                  | <input type="checkbox"/>     | Discrepancy noted in Clerical/Visual paper work check |
| <input type="checkbox"/>                                    | Visual inspection of the pre- and post-sample was normal             | <input type="checkbox"/>     | Hemolysis present in post transfusion sample          |
| <input type="checkbox"/>                                    | Pre and Post transfusion sample testing resulted in no discrepancies | <input type="checkbox"/>     | Discrepancy noted in sample testing                   |
| <input type="checkbox"/>                                    | There is no evidence of red cell incompatibility                     | <input type="checkbox"/>     | Evidence of red cell incompatibility                  |
| <input type="checkbox"/>                                    | Negative Gram stain (no organisms seen)                              | <input type="checkbox"/>     | Positive Gram Stain      Date/Time _____              |
| <input type="checkbox"/>                                    | Negative culture (no growth)   | <input type="checkbox"/>     | Positive Culture      Date/Time _____                 |
| Patient Pre-transfusion DAT: POLY <input type="checkbox"/>  |  | IGG <input type="checkbox"/> | C3 <input type="checkbox"/>                           |
| Patient Post-transfusion DAT: POLY <input type="checkbox"/> |  | IGG <input type="checkbox"/> | C3 <input type="checkbox"/>                           |

| REACTION CLASSIFICATION          |                                   |  |
|----------------------------------|-----------------------------------|--|
| <input type="checkbox"/> Febrile | <input type="checkbox"/> Allergic | <input type="checkbox"/> Other, See Comments |

| RECOMMENDATIONS and COMMENTS |  |
|------------------------------|--|
| <input type="checkbox"/>     | Pre-medication with antipyretics to reduce the incidence of febrile non-hemolytic reactions may be indicated |
| <input type="checkbox"/>     | Pre-medication with antihistamine and/or steroids may be indicated   |
| <input type="checkbox"/>     | Symptoms may be due to patient's underlying health conditions, clinical correlation is recommended           |
| Comments _____               |  |
| _____                        |  |
| _____                        |  |
| _____                        |  |

|   |                   |
|---|-------------------|
| Results called to: _____  | Date / Time _____ |
| Testing performed by: _____   | Date / Time _____ |
| Record reviewed by: _____   | Date / Time _____ |
| Report reviewed by the Medical Director on: _____                   | Date _____        |
| L.Sutor MD      G.Paranjape MD      W.Crews MD      T. Nishimoto MD |                   |

"+m" = Microscopic      "+w" = Weakly Positive      NT = Not Tested      Neg = Negative

# TRANSFUSION REACTION INVESTIGATION

|                                 |   |   |
|---------------------------------|---|---|
| <b>PATIENT INFORMATION</b>      | Patient Name _____ Identification Number _____  |   |
|                                 | Facility Name _____ Ordering Physician _____  |   |
|                                 | Diagnosis _____   |   |
| <b>INFUSIONIST REPORT</b>       | Unit Number(s) _____  |   |
|                                 | Component(s) Involved _____ Amount(s) Transfused _____  |   |
|                                 | All forms, labels and patient identification have been verified. <input type="checkbox"/> Yes <input type="checkbox"/> No   |   |
|                                 | Date / Time Transfusion Started _____   | Date / Time of Reaction _____               |
|                                 | Date / time Transfusion Stopped _____   | Infusionist _____                           |
|                                 | Person Completing Form _____  | Date / Time _____                           |
|                                 | Pre-Transfusion   | Post-Transfusion                            |
|                                 | Temperature _____   | Temperature _____                           |
|                                 | Pulse _____   | Pulse _____                                 |
|                                 | Blood Pressure _____  | Blood Pressure _____                        |
|                                 |   | Patient Symptoms                            |
|                                 | <input type="checkbox"/> Chills   | <input type="checkbox"/> Nausea             |
|                                 | <input type="checkbox"/> Fever  | <input type="checkbox"/> Urticaria          |
|                                 | <input type="checkbox"/> Dyspnea  | <input type="checkbox"/> Hematuria          |
|                                 | <input type="checkbox"/> Shock  | <input type="checkbox"/> Back or Chest Pain |
|                                 | <input type="checkbox"/> Jaundice   | <input type="checkbox"/> Other _____        |
| <b>INFUSIONIST INSTRUCTIONS</b> | <ol style="list-style-type: none"> <li>1. Immediately discontinue transfusion. Keep IV line open with normal saline (0.9% sodium chloride) or other FDA approved blood administration solution.</li> <li>2. Check all forms, labels, and patient identification.</li> <li>3. Notify attending physician and Carter BloodCare Reference and Transfusion Services.</li> <li>4. Properly collect and label post-transfusion purple top (EDTA) anticoagulated specimen. Minimum 3 ml sample required.</li> <li>5. Complete RTF215.01A Transfusion Reaction Investigation.</li> <li>6. Send samples, blood component container with attached administration set and intravenous solutions, compatibility tag, and this completed form to Carter BloodCare Reference and Transfusion Services <b>STAT</b>.</li> </ol> |   |

1. Document the following in the "Patient Information" section (you may apply a patient sticker):
  - Patient name
  - Patient identification number
  - Requesting facility
  - Ordering physician
  - Patient Diagnosis
2. Document the following in the "Infusionist Report" section:
  - Unit number(s)
  - Component(s) involved
  - Amount(s) transfused
  - Mark "Yes" or "No" box appropriately, indicating whether or not all forms, labels and patient identification have been verified.
  - Date/time of reaction
  - Infusionist
  - Name of person completing the form
  - Date/Time the form was completed
  - Pre-transfusion
    - Temperature (including unit of measure °F)
    - Pulse
    - Blood pressure
  - Post-transfusion
    - Temperature (including unit of measure °F)
    - Pulse
    - Blood pressure
  - Place a checkmark (✓) or "X" next to the applicable patient symptoms associated with transfusion.
  - Send back to the blood bank



## 7.0 COLLECTIONS

**Contact Information:**

Collections Department

Carter BloodCare

2205 Highway 121

Bedford, TX 76021

Phone: 1-800-DONATE-4 – to schedule an appointment

Phone: 817-412-5380 – to schedule a blood drive or to schedule health fair activities  
through our Recruitment Department

Collections Department

Carter BloodCare

815 South Baxter Avenue

Tyler, TX 75701

Phone: 1-800-252-5584 - to schedule an appointment

Phone: 903-363-0400 - to schedule a blood drive or to schedule health fair activities  
through our Recruitment Department

Collections Department

Carter BloodCare

206 Archway Drive

Woodway, TX 76721

Phone: 1-800-DONATE-4 – to schedule an appointment

Phone: 254-297-4000

For the most up-to-date information regarding hours of operations, driving directions or to schedule a donation appointment, please call 1-800-DONATE-4 or visit our interactive web site at [carterbloodcare.org](http://carterbloodcare.org).

## 7.1 Neighborhood Donor Centers

### NORTH TEXAS LOCATIONS

#### **Addison**

3955 Belt Line Road  
Addison, TX 75001  
972-960-8895

#### **Frisco**

4350 W. Main Street, Suite 105  
Frisco, TX 75033  
214-217-5690

#### **Allen \***

1328 W. McDermott Drive, Suite 250  
Allen, TX 75013  
214-509-0550

#### **Garland**

6850 N. Shiloh, Suite V  
Garland, TX 75044  
972-437-4483

#### **Arlington \***

1618 W. Randol Mill Road  
Arlington, TX 76012  
817-274-0812

#### **Grand Prairie**

4146 South Carrier Parkway, Suite 630  
Grand Prairie, TX 75052  
972-988-6051

#### **Cedar Hill**

613 Uptown Boulevard, Suite 107  
Cedar Hill, TX 75104  
972-572-3917

#### **Hurst-Euless-Bedford\***

1731 W. Airport Freeway  
Bedford, TX 76021  
817-283-4787

#### **Dallas\***

4201 Gaston Avenue, Suite 110  
Dallas, TX 75246  
214-572-3917

#### **Irving**

7750 N. MacArthur Boulevard, Suite 115  
Irving, TX 75063  
972-258-0055

#### **Dallas\***

12829 Preston Road, Suite 427  
Dallas, TX 75230  
972-980-9210

#### **Keller**

101 Town Center Lane, Suite 111  
Keller, TX 76248  
817-337-1520

#### **Denton**

2215 South Loop 288, Suite 335  
Denton, TX 76205  
940-383-2055

#### **Lockheed (Employees Only)**

1 Lockheed Boulevard  
White Settlement, TX 76108  
817-762-1551

#### **Flower Mound**

2601 Flower Mound Road  
Flower Mound, TX 75028  
972-219-1668

#### **Mansfield**

920 US Hwy 287N, Suite 210  
Mansfield, TX 76063  
817-539-0244

#### **Fort Worth\***

1263 West Rosedale  
Fort Worth, TX 7104  
817-335-4935

#### **Mesquite\***

1515 N. Town East Blvd. Suite 151  
Mesquite, TX 75150  
972-270-2185

#### **Fort Worth**

4995 South Hulen Street  
Fort Worth, TX 76132

## CARTER BLOODCARE SERVICE MANUAL

### Plano

4701 W. Parker, Suite 610  
Plano, TX 75093  
972-612-2098

### Weatherford

116 East I-20, Suite 151  
Weatherford, TX 76087  
817-594-4251

## EAST TEXAS

### Longview\*

3080 N. Eastman, Suite 112  
Longview, TX 75605  
903-663-2650

### Tyler\*

815 South Baxter Avenue  
Tyler, TX 75701  
903-363-0400

### Paris\*

3305 N.E. Loop 286, Suite E  
Paris, TX 75460  
903-785-9399

## CENTRAL TEXAS

### Woodway\*

206 Archway Drive  
Woodway, TX 7021  
254-297-4150

**\* Denotes Donor Centers accepting autologous, directed and therapeutic phlebotomy collections**

## 7.2 Blood Drive Information

Be a part of our community blood program!

Organizations may schedule blood drives with Carter BloodCare. Blood drives may be operated indoors, if the space meets the specific regulatory requirements or the blood drive may be held in one of our mobile buses.

If you are interested in scheduling a blood drive, one of our field consultants will visit with you to help with all necessary planning and promotion assistance. In addition, they are trained to provide in-services to your staff regarding blood donation.

If you are interested in scheduling a blood drive, please contact our Recruitment Department.

## 7.3 Health Fairs


Carter BloodCare actively supports and participates in community health fairs.

If your organization is planning to host a health fair and would like Carter BloodCare to participate, please call our Recruitment Department.

## DCL500 Restricted Donation Tag

Color is Orange

Front



Back



## 11.11 Return Policy and Request for Quarantine

Blood components may be returned for full credit under the following conditions:

- As outlined in your Blood Service Agreement.
- The safety, potency or purity of the blood component is in question.
- The product has not been manipulated, altered or defaced by the facility.
- Prior approval has been obtained from Carter BloodCare.

In the event blood products will be returned to Carter BloodCare for investigational purposes, please complete DPF-300.03A, Return of Blood For Investigation. An example of this form is included in the forms section. Once completed, phone Carter BloodCare's Distribution department requesting the component (s) to be retrieved

A product quarantine request may be faxed to your facility to confirm the verbal request to quarantine and return or discard the component if available. The request will be generated by the Distribution department.

## 11.12 Forms

- DPF200.20A, Fax order and Inventory Form
- DPF200.05, Hand Ship Ticket
- DPF300.03, Hospital Report of Returned Blood Components
- DPF300.03A, Return of Blood For Investigation
- DPF400.20A, Quarantine Request Facsimile
- DPF400.20B, Quarantine Release Request Facsimile
- DPF400.20C Notification/Quarantine Request Facsimilie



# Carter BloodCare

## NOTIFICATION/QUARANTINE REQUEST FACSIMILE

Facility: \_\_\_\_\_ Contact: \_\_\_\_\_

Fax: \_\_\_\_\_

From: Distribution – Hospital Services Department

Office: Bedford: Phone: 817-412-5700 Fax: (817) 412-5729

Tyler: Phone: 903-363-0404 Fax: (903) 363-0483

Waco/Central Texas: Phone: 254-297-4100 Fax: (254) 399-6391

Date: \_\_\_\_\_

### Total number of pages, including coversheet:

This fax is being sent as notification that your facility received a platelet product on \_\_\_\_\_ (date) which has now tested positive on the screening test for bacteria. If you have this product in inventory, it should be placed in quarantine for return to us at Carter BloodCare. If it has been transfused, we suggest notification of the transfusing physician of this finding.

Further testing will be done to determine if the platelet product is actually contaminated with bacteria or whether this is a false positive. Our sample has been sent for gram stain and secondary culture and possible bacterial identification. We will notify you of further information when we get the results.

Of note, this platelet product was testing culture negative at the time we shipped the unit to you, but the culture has subsequently turned positive in the intervening time.

If you or your medical staff has further questions, we can put you in touch with our medical director.

If these units are in your inventory, please quarantine them for return.

Unit returned by facility

| Unit Number | Product Code | Component Type | Blood Type | Ship Date |
|-------------|--------------|----------------|------------|-----------|
|             |              |                |            |           |
|             |              |                |            |           |
|             |              |                |            |           |

Fax received by: \_\_\_\_\_ Date: \_\_\_\_\_

**Sign this form and fax it back to Carter BloodCare using the appropriate fax number shown above, indicating receipt of this notification.**

IMPORTANT WARNING: This message is intended for the use of the person or entity to which is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by state and federal laws. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this message is strictly prohibited. If you have received this message by error, please notify Cater BloodCare at (817) 412-5000 immediately and destroy the related message.

## 12.0 REFERENCE AND TRANSFUSION SERVICES POLICIES

### Contact and Shipping Information:

Immunohematology Reference Laboratory and Transfusion Services

Carter BloodCare

2205 Highway 121

Bedford, TX 76021

Phone: (817) 412-5740

Fax: (817) 412-5749

Emergency Phone(s): (817) 685-1242

(817) 684-7391

Emergency Fax: (817) 283-1065

Distribution/Hospital Services

Bedford Phone: (817) 412-5700

Tyler Phone: (903) 363-0404

Hospital Relations

Phone: (817) 412-5328

**NOTE: The Test Information Chart is in its own section of this manual.**

### 12.1 GENERAL INFORMATION FOR PATIENT/REFERENCE TESTING SERVICES

Reference and Transfusion Services department staff are scheduled to provide coverage 24 hours a day, 365 days a year.

For quality control purposes, all incoming and outgoing calls of the Reference and Transfusion Services department are recorded.

The Reference and Transfusion Services department provides a wide range of services including:

- Provision of antigen negative units
- Crossmatch service
- Antibody identification (simple/complex)
- Platelet services (platelet antibody screen, crossmatch and/or HLA matched)

#### 12.1.1 Contract

A contract is required to initiate reference services. A signed contract ensures all involved parties adhere to current regulatory requirements. Additionally, a contract

allows the client to exchange PHI with CBC and CBC to provide the client patient care results. To initiate a contract, please contact the Hospital Relations department.

### **12.1.2 Requisitions**

The client is expected to utilize the appropriate requisition form. Requisition completion is detailed in the applicable parts of this section. Example copies of requisitions are included in the back of this section. Please contact the Reference and Transfusion Services department for questions regarding completing a requisition. Requisitions may be obtained from [carterbloodcare.org](http://carterbloodcare.org) or the Hospital Relations department.

Please complete the appropriate requisition fully. Accurate information is vital for test completion. It is helpful to provide as much detail as available to allow the laboratory to make a complete evaluation and report.

### **12.1.3 Specimen Collection and Preparation**

Proper specimen collection and preparation is essential in order to provide a timely, accurate test result and is required by accreditation agencies. Please follow the sample collection requirements listed in the Test Information Chart. Please contact the Reference and Transfusion Services department for any questions.

#### **Clearly label each specimen with the following information:**

- Patient's full name as recorded in the medical record
- Patient's identification number (i.e., medical record number, birth date, or any other unique identification system utilized by the client)
- Collection date (month, day, year)
- Collection time
- Collector's initials
- Blood Bank ID number (if applicable)

#### **Please inspect each sample tube to ensure:**

- Information is clear and legible
- No defacement, tearing, or alteration of the label has occurred
- No broken or cracked tube
- The tube stopper is intact

It is important to follow manufacturer instructions for all drawing supplies. Please pay careful attention that anticoagulated specimens are properly mixed and are not hemolyzed.



#### **12.1.4 Sample Shipping Requirements**

Please notify Reference and Transfusion Services department in advance of sending a sample. Advance notice will help the department staff ensure the specimen and the request are handled more efficiently.

**Samples for testing and the accompanying paperwork should  
Be delivered to:**

Reference and Transfusion Services  
Carter BloodCare  
2205 Highway 121  
Bedford, TX 76021

**Samples may be delivered to Carter BloodCare by:**

- Calling the Reference and Transfusion Services department to arrange for a sample pick up. There are additional charges associated with this service.
- Utilizing your own courier to deliver the samples.

Samples should be packaged in a leak-proof container. OSHA requires that all samples be marked as biohazards.

Samples may be delivered to the Reference and Transfusion Services department 24 hours a day, 365 days a year.

#### **12.1.5 Unacceptable Specimens**

**IMPORTANT:** As an AABB accredited laboratory, Carter BloodCare rejects incomplete or inaccurately labeled specimens. Specimens will be rejected without proper documentation. Proper identification of samples is essential if Carter BloodCare is to provide accurate laboratory results for the correct patient. The Reference and Transfusion Services department will not accept unlabeled specimens, even when accompanied by paperwork bearing the patient's name.

Sample integrity is crucial to achieving accurate test results. Samples cannot be compromised due to conditions during collection, transport, or storage. The most frequent causes of unacceptable samples are hemolysis, incorrect sample type, and insufficient sample volume.

If a sample is rejected for any reason, the client will be notified by phone. A follow up Specimen Rejection Report will be faxed or sent to the client noting the reason for specimen rejection. An example copy of the Specimen Rejection Report is included in the back of this section.

### 12.1.6 Available Tests

Available tests are listed in the Test Information Chart section 10.0 of this manual. Tests implemented after the printing of this manual may not be listed. For information on new or available tests, please call the Hospital Relations department.

### 12.1.7 Test Priority (Does Not Include Delivery Time)

#### STAT Order:

STAT describes a situation where unnecessary delay in testing would endanger the life of the patient.

If ordering specific blood products STAT, use of this term implies that no unit of blood exists within the hospital's assigned inventory suitable to meet the need. The Reference and Transfusion Services department, in conjunction with the Distribution department, will utilize any means available to fill a STAT blood product order including use of short-dated units. In the event that units are not readily available, Carter BloodCare will go to any lengths necessary to obtain the desired units including:

- Testing units in stock inventory
- Obtaining units from hospital inventory
- Deglycerolizing frozen units
- Making arrangements to import units from other blood centers

The Reference and Transfusion Services department staff will provide the client with continual updates

Under normal circumstances, STAT turn-around-time is **2 HOURS** - that is, products ordered STAT will be *dispensed for shipment* within two hours from receipt of the order. Exceptions may apply if the order is for a large quantity of blood components, if the blood product must have special testing or manipulation prior to shipment including irradiation, washing, reconstitution, if blood products must be located from an outside source, or if the order involves a complex serological workup.

Because proper communication is essential during a STAT situation, Carter BloodCare will keep the client informed of all steps taken to provide the requested products. In turn, Carter BloodCare asks that it receives timely updates regarding the patient's status, especially if the situation is no longer determined to be STAT.

#### ASAP (As Soon As Possible) Order:

ASAP may be applied to any order, other than STAT, to notify the Reference and Transfusion Services department that routine testing turn-around-time will not be suitable due to specific, clinical time restraints. *Please specify the date and time of expected delivery.*

## CARTER BLOODCARE SERVICE MANUAL

Under normal circumstances, ASAP turn-around-time is **4 HOURS** - that is, products ordered ASAP will be *dispensed for shipment* within four hours from receipt of the order. Exceptions may apply if the order is for a large quantity of blood components, if the blood product must have special testing or manipulation including irradiation, washing, or reconstitution prior to shipment, if blood products must be located from an outside source, or if the order involves complex serological workup.

### **Routine Order:**

A Routine order is placed when there are no specific, clinical time restraints.

Routine order turn-around-time is **8 HOURS** from the time the order is received. That is, products included in a Routine Order will be dispensed for shipment within eight hours from receipt of the order.

| <b><i>Test Priority</i></b> | <b><i>Target Turn-around time</i></b> |
|-----------------------------|---------------------------------------|
| STAT                        | 2 hours                               |
| ASAP                        | 4 hours                               |
| Routine                     | 8 hours                               |

### **12.1.8 Test Cancellation**

Tests may be canceled without charge if the cancellation notification is received prior to starting the test. If the test request is for profile (grouped) testing, the client will be charged for any test started before the test cancellation notification is received.

### **12.1.9 Results, Reports, Requests for Quarantine, Product Investigation Notification, and Requests for Historical Patient Antibody Testing Information**

#### **Verbal Report:**

A telephoned verbal report is provided, if requested. The client will be notified when complex or difficult serological test cases necessitate a time delay. Information on anticipated turn-around time will be given on a case by case basis. Additional verbal reports will be provided upon request.

#### **Preliminary Report:**

A preliminary test result report and billing statement will be faxed upon completion of the testing or included with a shipment if blood products are requested.

### **Written Report:**

A detailed written Immunohematology Report will be faxed after testing is completed. The detailed report includes all test results. If a final report is not received or there are questions concerning the final report, please contact the Reference and Transfusion Services Department.

### **Requests for Quarantine:**

A product quarantine request may be faxed to your facility to confirm the verbal request to quarantine and return the component if available. The request may be generated by the Reference and Transfusion (R/T), the Records Audit and Data Entry (RADE) department and Distribution.

### **Requests for Historical Patient Antibody Testing Information:**

Facilities may request information regarding previous antibody testing performed by Carter BloodCare. Complete patient information section of form RTF103.01A, Reference and Transfusion Service Patient Historical Record Check Request, and fax to 817-412-5749. The form will be completed and returned to your facility with any applicable historical information. A faxed request form is required to obtain information; verbal requests for historical information will not be accepted.

## **12.1.10 Emergency Release of Untested Components**

In the event of an extreme emergency situation, Carter BloodCare may release components prior to completion of all testing. A Carter BloodCare physician must approve the shipment of any untested emergency released component. Incomplete results may include antigen screening and confirmation (for antigen negative RBCs), or infectious disease testing (for units still in processing). All emergency released untested components are ABO/Rh tested prior to release.

### **12.1.10.1 Requesting Emergency Released Untested Components**

A written physician's statement of need must be completed in order for Carter BloodCare to emergency release untested components. In addition, the physician must complete Blood Release Form RTF214.03 and fax it to Reference and Transfusion. Upon receipt of the signed form, the Reference and Transfusion Services department staff will locate the requested components.

### **12.1.10.2 Labeling and Accompanying Paperwork for Emergency Released Untested Components**

- Emergency released untested components are tagged with an Emergency Release Untested Component tie tag that specifically lists all pending tests.

- Blood Release Form RTF214.03 is sent with the labeled component *and must be completed and returned to CBC.*

### **12.1.11 Notification of Pending Test Completion**

Upon completion of testing, the client will be notified by fax of the test results. If there are any reactive results the client will be notified immediately.

## **12.2 REFERENCE TESTING SERVICES – RED BLOOD CELLS**

### **12.2.1 Serological Testing**

The Reference and Transfusion Services department offers the following serological testing:

- ABO/Rh typing including Rh phenotyping
- ABO/Rh type discrepancy resolution
- Antigen typing
- Antibody screen and identification, routine and complex
- Compatibility testing
- Serological testing consultation

#### **Sample Requirements for Serological Testing**

Sample requirements for serological testing are described in the Test Information Chart.

#### **Requisition for Serology Testing**

Complete form RTF101.01A, Reference and Transfusion Services Request Form, with the following information:

- Patient's full name, as it appears in the medical records
- Patient identification used by requesting facility
- Requesting physician
- Sample collection information
- Requesting facility
- Patient information: diagnosis, gender, date of birth, transfusion history and pregnancy history (if applicable)
- Serological testing services requested
- Test priority: (Please ensure the appropriate test priority is indicated. Requisitions not marked with specific test priority will be assumed to be for routine testing.
- Results of known serological findings, if applicable.
- Special instructions, if applicable, for component(s) requested.

### 12.2.2 Red Blood Cell Antigen Screening

The Reference and Transfusion Services department will make every attempt to provide antigen negative red blood cell components for patients with clinically significant antibody(ies).

The Reference and Transfusion Services department maintains a special inventory of antigen negative liquid red blood cells. If the requested antigen negative blood is not readily available in the inventory, staff will screen units in regular inventory to find the requested antigen negative units. A frozen inventory of antigen negative units is also maintained. Frozen/deglycerolized antigen negative units may be substituted when no liquid antigen negative units are available. If no frozen or liquid units are available to fill the request, the Reference and Transfusion Services department staff will contact the client and make arrangements to import antigen negative units from outside sources.

Antigen screening of red blood cells for clinically insignificant antibodies will not be routinely performed. Carter BloodCare follows recommendations outlined in current transfusion medicine literature. Anti-A<sub>1</sub>, anti-P<sub>1</sub>, anti-M, anti-N, anti-Le<sup>a</sup>, and anti-Le<sup>b</sup> antibodies which are reactive at room temperature and/or at the complement phase of AHG testing are not considered to be clinically significant. A sample may be requested to verify the need for antigen negative units when associated with clinically insignificant antibodies or if the request requires the utilization of the American Rare Donor Program (ARDP).

ABO group compatible units will be provided.

If the request is for a **rare** unit, the Reference and Transfusion Services staff may request a sample of the patient's blood to reconfirm the antibody or to use for red blood cell screening.

#### Requisition for Serology Testing

Complete form RTF101.01A, Reference and Transfusion Services Request Form as described in Section 12.2.

### 12.2.3 Red Blood Cell Crossmatch Services

The Reference and Transfusion Services department performs crossmatching and blood component preparation as requested.

#### Requisition for Crossmatch Services

Complete form RTF101.01A, Reference and Transfusion Services Request Form as described in Section 12.2. The services requested would include the provision of crossmatched red blood cells.

## CARTER BLOODCARE SERVICE MANUAL

In the top section of the form, record the Blood Bank ID # as it is noted on the patient identification armband if applicable. The ID # may be in any format used by the client, including Typenex numbers or Hollister numbers. Blood Bank ID armbands may be purchased from Carter BloodCare. An identification armband is required to be on the patient if crossmatching is to be performed by Carter BloodCare. Ask the Reference and Transfusion Services department for details on purchasing armbands.

Retain the yellow copy of the requisition form to include in the patient's chart.

Submit the top copy (white) with sample.

### Patient Identification

**Correct patient identification is a critical step in providing safe transfusion therapy.** The following instructions are recommended for proper patient identification prior to blood sample collection. These instructions are recommended steps only. Be sure to follow all pertinent procedures at the transfusion facility.

NOTE: If platelets, plasma or cryoprecipitate are requested and the patient has been previously blood typed by Carter BloodCare, a blood sample does not need to be collected. For verification of sample collection, please contact the Reference and Transfusion Services department.

### Recommended procedure for patient identification:

- The patient must be wearing an identification armband. The armband must not be removed from the patient after blood sample collection. Special Blood Recipient Identification armbands are designed for use in correlating positive identification of the blood recipient (patient), patient blood samples, the patient request form, and the blood components intended for the patient. These armbands are placed on the patient immediately before sample collection and must contain all required information.
- The phlebotomist or nurse must bring the completed Reference and Transfusion Services Request form to the patient's bedside or chair side when the blood sample is drawn to verify correct patient information. If the patient is alert and coherent, ask the patient to state his/her name. Be certain the patient is not under the influence of alcohol, mind-altering drugs, or strong analgesics. Verify that the name stated matches the name on the request form. Verify that the name and the patient identification number on the form match the name and patient identification number on the patient armband.
- Do not draw blood samples unless the patient's name and patient identification number on the armband exactly match the information recorded on the request form.
- Do not draw blood samples unless the name stated by the patient (provided the patient is alert and coherent) exactly agrees with the name on the request form.
- Do not use bed labels, patient's chart or door labels as patient identification.

## CARTER BLOODCARE SERVICE MANUAL

- Note the date blood component(s) are requested on the request form.

### Blood Sample Collection

- Samples for crossmatch should not be drawn more than **three days** in advance of the scheduled day of transfusion. Samples are valid for three days.
- Collect 15mls of patient sample in an EDTA tube.
- See Test Chart Information Section 10.0 for specific sample requirements.
  - Samples must be collected according to instructions listed previously in this section. See General Information.
  - Samples should not be hemolyzed.
  - Samples should not be collected from an intravenous infusion site.
  - Samples should not be drawn proximal to an intravenous infusion site.

### Blood Sample Labeling Requirements

- Samples must be labeled with:
  - Patients full name
  - Patient's ID
  - Collection date (month, date, year)
  - Collection time
  - Collector's initials

**\*\* The above items **must be** on the sample tube\*\***
- Labels must have clear, identical, legible information. Do not use markers or gel pens.
- The patient's blood samples must be labeled at the time of collection at the patient's bedside or chair side by the phlebotomist or nurse collecting the sample.
- If a Blood Recipient Identification Band is used, place one of the numbered stickers on the request form or hand write in the Blood Bank ID# box. Place a numbered sticker on each labeled tube submitted for testing.
- Send all additional blood bank stickers with the white copy of the completed Reference and Transfusion Services request form.

### Completion and Delivery of the Crossmatch and Component Request by Carter BloodCare

- Upon receipt of the request form and blood sample tubes, all information will be carefully checked to ensure proper patient and sample identification is maintained.
- When the compatibility and crossmatch testing is complete, the units will be tagged with a Carter BloodCare Compatibility Tag (an example of the tag is included at the back of this section).
- If a Blood Recipient Identification Band was used and if the numbered stickers were sent with the patient's blood sample, a numbered sticker will be placed on each blood component intended for the patient. If the numbered stickers were not sent, the number will appear on the compatibility tag only and not on the product.



## CARTER BLOODCARE SERVICE MANUAL

- The expiration of the crossmatch is **three days** from the date the blood sample for crossmatch was collected. Red blood cells crossmatched for a patient, but not transfused will be released when the crossmatch expires. NOTE: A crossmatch fee will be charged for red cells that are crossmatched but not requested for delivery or pick-up.
- Corresponding paperwork which will be sent with the crossmatched unit:
  - Pack List with each product shipment (see example in the Finance/Billing section of this manual).
  - Carter BloodCare Compatibility Tag.
- If Carter BloodCare has arranged the component delivery, a staff member at the facility will be asked to sign either the Pack List or the courier delivery ticket as verification of product receipt.

### Component Delivery/Pick-Up

- Carter BloodCare does not deliver products directly to a patient's home for home transfusion.
- If a client is going to pick-up components from Carter BloodCare:
  - Carter BloodCare transport container will be utilized and the facility may be charged for the container. For questions regarding transport containers, please call the Distribution department.
  - Carter BloodCare staff will pack the component(s) according to regulations.

### Crossmatched Product Return Policy

Carter BloodCare may accept return of unused crossmatched components under the following conditions:

- The component has been properly stored under approved storage conditions. Proof of appropriate storage conditions must be provided on Hospital Report of Returned Blood Components, DPF 300.03 (an example of the form is located at the back of Section 11.0)
- The component is in-date.
- Products must be approved in advance for return.

### Instructions to Infusionist

**Accurate identification of the recipient and donor unit is one of the most critical steps for a safe transfusion.** The following instructions are recommended for proper patient identification prior to product infusion. These instructions are recommended steps only. Be sure to follow all pertinent procedures at the transfusion facility.

Before blood product administration, the nurse who will be administering the blood component must verify all information. Whenever possible, a second verification should

## CARTER BLOODCARE SERVICE MANUAL

be performed by licensed personnel or according to internal policy. The following information must be verified:

- Patient's name and identification number on the armband exactly matches the patient's name and identification number on:
  - The yellow copy of the request form.
  - The Compatibility Tag attached to the blood component.
- If a discrepancy is noted, or if the patient's armband is not present, do not transfuse the component. Immediately notify the Reference and Transfusion Services department.
- Verify that the blood type and unit number on the blood component label matches the blood type and unit number on:
  - The Compatibility Tag attached to the blood component.
  - The information recorded on the Pack List.
- If a discrepancy is noted, do not transfuse the component. Immediately notify the Reference and Transfusion Services department.
- Verify the component is in-date and is not expired. Do not infuse the component if it is expired. Immediately notify the Reference and Transfusion Services department.
- Verify the numbered sticker on the blood component exactly matches the numbered sticker on the patient's Blood Recipient Identification Band. If a discrepancy is noted, do not transfuse the component. Immediately notify the Reference and Transfusion Services department.

### Following Component Infusion

Following successful component infusion, complete the information on the Compatibility Tag attached to the blood component bag. Carter BloodCare automatically applies a presumed transfused final disposition; therefore, the Compatibility Tag should be retained by the facility for internal medical record use.

## 12.3 REFERENCE TESTING SERVICES – PLATELETS

Carter BloodCare provides HLA matched apheresis platelets, platelet crossmatches, and can send your patient samples to an outside HLA testing laboratory in the event you do not have an HLA type available on your patient.

A patient receiving multiple platelet components may become refractory as a result of immunization. The patient may require HLA-matched or crossmatch compatible apheresis platelet components to achieve a satisfactory increase in platelet counts.

Other causes of thrombocytopenia, i.e., fever, infection, splenomegaly, medications, bleeding, or DIC should be evaluated by a clinician. If these other causes of poor response to platelet transfusions exist, the ordering and transfusion of special platelet products cannot be expected to provide an appropriate transfusion response.

**12.3.1 HLA matching**

HLA typing is performed on Carter BloodCare apheresis donors for subsequent matching with a patient. The requesting Transfusion Service must provide the patient's HLA, class I (A & B) type in writing. The donor's HLA type is computer matched to the patient's HLA type. The best available match grade will be provided. Match grades of C or below are not routinely used.

| Donor Classification | Description   |
|----------------------|---|
| A                    | All four antigens in donor identical to those in recipient  |
| BIU                  | Three antigens detected in donor; all present and identical in recipient                            |
| BIX                  | Three donor antigens identical to recipient; fourth antigen cross-reactive with recipient           |
| B2U                  | Two antigens detected in donor; both present and identical in recipient                             |
| B2UX                 | Three antigens detected in donor; two identical with recipient, third cross-reactive with recipient |
| B2X                  | Two donor antigens identical to recipient; third and fourth antigens cross-reactive with recipient  |
| C                    | One antigen of donor not present in recipient and non cross-reactive with recipient                 |
| D                    | Two antigens of donor not present in recipient and non cross-reactive with recipient                |

If a donor with the required HLA type is not available at Carter BloodCare, Reference and Transfusion Services department staff will make every attempt, within reasonable means, to locate an acceptable HLA match. This includes, but is not limited to, calling specific donors to donate apheresis platelets or importing apheresis platelets from other sources.

Because of the difficulty in finding appropriate matches, it is highly recommended to notify the Reference and Transfusion Services in advance for the need of HLA matched platelets. This will allow time for donor recruitment, collection, and processing of an acceptable HLA matched product.

### **12.3.2 Platelet Antibody Screening and Crossmatching**

Enzyme-Linked Immunoassay is used for screening of patient platelet antibodies. The presence of patient platelet antibodies directed against an antigen found on donor platelets would render ineffective or shorten the life expectancy of the transfused platelets. In platelet antibody screening, the patient's serum is tested against a routine panel of characterized platelets. The panel includes the following platelet glycoprotein serological specificities: HPA-1, HPA-2, HPA-3, HPA-4, and HPA-5. In addition, some antibodies directed toward some HLA specificities are detected by this method. A platelet antibody screen is recommended on a patient before crossmatching apheresis platelet components. Solid phase technology is utilized when crossmatching patient serum against apheresis donor platelets. It is recommended that the Reference and Transfusion Services department be notified in advance for the need for platelet testing.

### **12.3.3 Requesting Platelet Testing Services**

Complete form RTF101.01A, Reference and Transfusion Services Request as described in Section 12.2.

- Please indicate special platelet components needed

If platelet testing services will be needed on specific dates, please note this on the requisition form.

### **12.3.4 Sample Requirements for Platelet Testing Services**

Specific sample requirements:

Samples must be collected and labeled according to instructions listed previously in this section. See 12.1, General Information for patient/reference testing services.

- Please refer to Section 10.0, Test Information Chart, for specific sample requirements for platelet antibody screens, compatible platelet crossmatch and HLA testing.

**NOTE:** Serum separator tubes are not acceptable.

### **12.3.5 Platelet Labeling**

HLA matched platelets are indicated as such on a yellow tie tag attached to the component. Information on the tag includes:

- Patient name
- Patient Identification number
- Hospital/Facility
- Unit Number
- Grade/interpretation of HLA match

Crossmatched platelet components are indicated as such by a manila tie tag attached to the component. Information on the tag includes:

## CARTER BLOODCARE SERVICE MANUAL

- Patient name
- Patient Identification number
- Hospital/Facility
- “Platelet Crossmatched” circled on one side and stamped on the reverse side

### **12.4 MOLECULAR TESTING SERVICES (AABB ACCREDITED)**

- Donor and Patient RBC genotyping/ Predicted phenotype testing (Common and Rare Antigen Systems)
- Discrepancy Resolution and 24/7 Consultation Services
- Handling of Specialized testing (i.e. RHCE and DNA sequencing)

### **12.5 PREVENTATIVE MAINTENANCE SERVICES**

- Pipette Calibration and Maintenance
- Digital Timer Calibration
- Thermometer Standardization

### **12.6 Example Reports:**

- RTF102.03, Immunohematology Final Report
- RTF102.04, Preliminary Report
- RTF104.15, Reference and Transfusion Specimen Rejection Report

### **12.7 Example Forms:**

- APL100, Apheresis Product Tag
- APL100, Crossmatched Apheresis Product Tag
- RAF601.00, Request for Product Quarantine, Records Audit and Data Entry
- RTF101.01A, Reference and Transfusion Services Request Form(2 part carbonless)
- RTF103.01A, Reference and Transfusion Service Patient Historical Record-Bedford
- RTF120.11A, Request for Product Quarantine, Discard, or Retrieval
- RTF120.11D, Reference and Transfusion Suspected Component Contamination Notification
- RTF214.01, Uncrossmatched Product Release
- RTF214.03, Untested Product Release form
- RTL214.01, Emergency Release Uncrossmatched Blood Label
- RTL214.03A, Previous Donation Results Label
- RTL214.03B, Testing Not Performed Label
- RTL422.01, HLA Matched Tie Tag
- Non-Crossmatch Compatibility Tag
- Crossmatch Compatibility Tag
- RTL207.01A Confirmed Antigen Typing
- RTL207.01C Molecular Matched Antigen Typing



REFERENCE AND TRANSFUSION SERVICES
IMMUNOHEMATOLOGY FINAL REPORT

Patient Name, ID Number, Requesting Facility, Ordering Physician, Sample Collection Date & Source, Date Request Received, Test(s) Requested, Patient Date of Birth & Gender

ABO/RH TYPE table with columns for ABO, Rho (D), RH Phenotype, RH2, RH3, RH4, RH5, Probable Rh-hr, and Genotype

ADDITIONAL RED CELL ANTIGEN TYPE table with columns for MNS1, MNS2, MNS3, MNS4, KEL 1, KEL 2, FY1, FY2, JK1, JK2, P1PK1, LE1, LE2, etc.

DIRECT ANTIGLOBULIN TEST form with columns for POLY, IgG, C3, ELUATE

ANTIBODY(IES) IDENTIFIED table with columns for Anti-, LISS (37°C, IgG), PeG IgG, Gel IgG, Solid Phase IgG, and Comments

ADDITIONAL DETAILS and TRANSFUSION RECOMMENDATIONS sections

Testing performed by, Record reviewed by, Report reviewed by the Medical Director on, Date & Time, Date



REFERENCE AND TRANSFUSION SERVICES  
IMMUNOHEMATOLOGY FINAL REPORT

|                      |  |                                  |  |
|----------------------|--|----------------------------------|--|
| Patient Name:        |  | Sample Collection Date & Source: |  |
| ID Number:           |  | Date Request Received:           |  |
| Requesting Facility: |  | Test (s) Requested:              |  |
| Ordering Physician:  |  | Patient Date of Birth & Gender:  |  |

ADDITIONAL DETAILS

TRANSFUSION RECOMMENDATIONS

|   |  |              |  |
|---|--|--------------|--|
| Testing performed by:                       |  | Date & Time: |  |
| Record reviewed by:                         |  | Date & Time: |  |
| Report reviewed by the Medical Director on: | L.Sutor MD   G.Paranjape MD   W.Crews MD   T. Nishimoto MD | Date:        |  |

\*+m\* = Microscopic

\*+w\* = Weakly Positive

NT = Not Tested

Pre/Prev = Previous



REFERENCE AND TRANSFUSION SERVICES

**PRELIMINARY REPORT**

Additional testing and review may be in progress.

|  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
|--|--|---------|------|--------------|------|-------------|----------|-------|----------------|----------------|-------|-------|--|--|--|--|--|--|--|
| Patient Name: <input style="width:90%;" type="text"/><br>ID Number: <input style="width:90%;" type="text"/><br>Requesting Facility: <input style="width:90%;" type="text"/><br>Ordering Physician: <input style="width:90%;" type="text"/> | Sample Collection Date & Source: <input style="width:90%;" type="text"/><br>Date Request Received: <input style="width:90%;" type="text"/><br>Test (s) Requested: <input style="width:90%;" type="text"/><br>Patient Date of Birth & Gender: <input style="width:90%;" type="text"/> |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| <b>ABO/RH TYPE</b>   |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| ABO  |  | Rho (D) |      | RH Phenotype | RH2  | RH3         | RH4      | RH5   | Probable Rh-hr |                |       |       |  |  |  |  |  |  |  |
|  |  |         |      |              | C    | E           | c        | e     | Genotype       |                |       |       |  |  |  |  |  |  |  |
|  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| <b>ADDITIONAL RED CELL ANTIGEN TYPE</b>  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| MNS1   | MNS2   | MNS3    | MNS4 | KEL 1        | KEL2 | FY1         | FY2      | JK1   | JK2            | P1PK1          | LE1   | LE2   |  |  |  |  |  |  |  |
| M  | N  | S       | s    | K            | k    | Fy(a)       | Fy(b)    | Jk(a) | Jk(b)          | P <sub>1</sub> | Le(a) | Le(b) |  |  |  |  |  |  |  |
|  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| <b>DIRECT ANTIGLOBULIN TEST</b>  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| POLY   |  | IgG     |      | C3           |      | ELUATE      |          |       |                |                |       |       |  |  |  |  |  |  |  |
| <b>ANTIBODY(IES) IDENTIFIED</b>  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
|  |  | LISS    |      | PeG          | Gel  | Solid Phase | Comments |       |                |                |       |       |  |  |  |  |  |  |  |
|  |  | 37°C    | IgG  | IgG          | IgG  | IgG         |          |       |                |                |       |       |  |  |  |  |  |  |  |
| Anti-  | Reactive by  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| Anti-  | Reactive by  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| Anti-  | Reactive by  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| Anti-  | Reactive by  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| Anti-  | Reactive by  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| Anti-  | Reactive by  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| <b>ADDITIONAL DETAILS</b>  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
|  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| <b>TRANSFUSION RECOMMENDATIONS</b>   |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
|  |  |         |      |              |      |             |          |       |                |                |       |       |  |  |  |  |  |  |  |
| Testing performed by: <input style="width:90%;" type="text"/>  |  |         |      |              |      |             |          |       |                |                |       |       |  |  | Date & Time: <input style="width:90%;" type="text"/> |  |  |  |  |





# REFERENCE AND TRANSFUSION SERVICES

## PRELIMINARY REPORT

Additional testing and review may be in progress.

|                      |  |                                  |  |  |
|----------------------|--|----------------------------------|--|--|
| Patient Name:        |  | Sample Collection Date & Source: |  |  |
| ID Number:           |  | Date Request Received:           |  |  |
| Requesting Facility: |  | Test (s) Requested:              |  |  |
| Ordering Physician:  |  | Patient Date of Birth & Gender:  |  |  |

### ADDITIONAL DETAILS

### TRANSFUSION RECOMMENDATIONS

|                       |  |              |  |  |
|-----------------------|--|--------------|--|--|
| Testing performed by: |  | Date & Time: |  |  |
|-----------------------|--|--------------|--|--|

\*+m\* = Microscopic

NT = Not Tested  
Copyright © 2018

Pre/Prev = Previous

Carter BloodCare  
2205 HWY 121  
Bedford, TX 76021  
(p)817-412-5740  
(f)817-412-5749  
CLIA#45D0486046  
AABB IRL #95

RTF102.04  
Version: 10  
Effective Date: 04/02/2018



REFERENCE AND TRANSFUSION SERVICE
PATIENT HISTORICAL RECORD CHECK REQUEST - BEDFORD

Patient's Name: Alias (if applicable): DOB:

Blood Type (if applicable): Other:

Requesting Facility: Requested by: Date Requested:

Facility Fax number: Facility Phone number:

The section above is to be completed by the customer and faxed to the R&T Laboratory at: (817)412-5749

The section below is to be completed by the Carter BloodCare R&T Laboratory:

- No Historical Patient Record Found
Historical Patient Record Found (Refer to information below)
Positive Patient Identification Not Possible with Current Information

Blood Type (if applicable): Historical Antibody(ies): anti-

- Serological
Molecular

Red Cell Antigen Type:

Table with 17 columns: RH2, RH3, RH4, RH5, MNS1, MNS2, MNS3, MNS4, KEL1, KEL2, FY1, FY2, JK1, JK2, P1, LE1, LE2. Row 1: C, E, c, e, M, N, S, s, K, k, Fya, Fyb, Jka, Jkb, P1, Lea, Leb.

P = Positive N = Negative

Comments:

Historical Patient Record Check Performed by: Date:

Disclaimer:

All efforts were made to match the patient information listed above with our records; however, positive patient identification cannot be guaranteed. The results provided should only be used in correlation with your own facility's testing records.

The information contained in this facsimile message is privileged and confidential information intended only for the use of the individual or entity named above. If you have received this information in error, please notify us immediately by telephone at Reference and Transfusion Services Carter BloodCare phone (817)412-5740.



# REQUEST FOR PRODUCT QUARANTINE, DISCARD OR RETRIEVAL

Date: \_\_\_\_\_ Facility: \_\_\_\_\_

Facility Contact: \_\_\_\_\_ Facility Fax: \_\_\_\_\_

From: Carter BloodCare – Reference & Transfusion Service Department \_\_\_\_\_  
(Employee Name)

Phone: (817) 412-5740

Number of Pages: \_\_\_\_\_

This facsimile is to follow up the telephone notification you received from the R&T department requesting the disposition of the unit(s) listed below. If this unit(s) is currently in your inventory, please **immediately** quarantine and arrange return to Carter BloodCare through the Distribution department, unless otherwise instructed by a Carter BloodCare representative.

Unit Number(s): \_\_\_\_\_

Product Code(s): \_\_\_\_\_

Blood Type(s): \_\_\_\_\_

Date(s) Shipped: \_\_\_\_\_

---

### To be completed by the customer and faxed back to the CBC Quality Assurance Department:

Fax: (817) 412-5659

If the facility was able to provide the below requested information to the R&T representative during the telephone conversation the R&T representative may have already completed the information below. In that case no further action is required by the facility at this time.

Status of the product (please mark applicable status and enter date(s), if applicable):

Available       Transfused    Date: \_\_\_\_\_       Discarded    Date: \_\_\_\_\_

Completed by: \_\_\_\_\_ Date: \_\_\_\_\_  
(Facility Name / Facility Representative Full Name)

---

*IMPORTANT WARNING: This message is intended for the use of the person or entity to which is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by state and federal laws. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this information is strictly prohibited. If you have received this message by error; please notify Carter BloodCare at (817)412-5740 immediately and destroy the related message.*

---

## REFERENCE AND TRANSFUSION SUSPECTED COMPONENT CONTAMINATION NOTIFICATION

Date/Time: \_\_\_\_\_ Facility: \_\_\_\_\_

Facility Contact: \_\_\_\_\_ Facility Fax: \_\_\_\_\_

From: Carter BloodCare – Reference & Transfusion Service Department \_\_\_\_\_  
(Employee Name)

Phone: (817) 412-5740

This facsimile is to follow up the telephone notification you received from the R&T or Distribution Department(s) requesting the disposition of the unit(s) listed below.

Unit Number(s): \_\_\_\_\_

Product Code(s): \_\_\_\_\_

Blood Type(s): \_\_\_\_\_

Date(s) Shipped: \_\_\_\_\_

Date/Time Transfused: \_\_\_\_\_

Patient Name (if applicable): \_\_\_\_\_ Patient MR# (if applicable): \_\_\_\_\_

Patient DOB (if applicable): \_\_\_\_\_

- This product tested positive for the screening test for bacterial detection after distribution (negative at the time of distribution.) Gram stain and culture results to follow.
- Other product(s) associated with the donation tested positive for the screening test for bacterial detection. Gram stain and culture results to follow.

Confirmatory Testing is as follows:

Gram Stain Results:     No Organisms Seen     Other \_\_\_\_\_

Gram Stain Results called to: \_\_\_\_\_ By: \_\_\_\_\_ on (Date/Time): \_\_\_\_\_

Final Culture Result:     No Growth                       Organism Isolated

Final Culture Results called to: \_\_\_\_\_ By: \_\_\_\_\_ on (Date/Time): \_\_\_\_\_

---

*IMPORTANT WARNING: This message is intended for the use of the person or entity to which is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by state and federal laws. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this information is strictly prohibited. If you have received this message by error; please notify Carter BloodCare at (817)412-5740 immediately and destroy the related message.*

---

## 13.0 Clinical Apheresis Services

### Contact Information:

To initiate a contract or to inquire about procedures or services, please contact:

Clinical Apheresis Services  
5550 LBJ Freeway, Suite 350  
Dallas, TX 75240  
Phone: (972) 788-0650

Christopher Edmond, RN,BSN  
Manager, Cellular Therapy Collections  
Cell: (817) 899-5765  
[ccedmond@carterbloodcare.org](mailto:ccedmond@carterbloodcare.org)

Pamela Malvern, BSN,RN,CNN  
Manager, Clinical Apheresis  
Cell: (817) 716-3622  
[pmalvern@carterbloodcare.org](mailto:pmalvern@carterbloodcare.org)

To schedule a therapeutic procedure 24/7, please call: (972) 788-0650.

For granulocyte orders 24/7, please call pager: (817) 482-9446.

### 13.1 Therapeutic Apheresis Services

Carter BloodCare provides mobile therapeutic apheresis procedures throughout the north Texas area, including Dallas/Ft Worth greater metroplex. This service is provided for hospitals that do not have apheresis programs, but also may serve as a back-up program for hospitals that do provide apheresis services but need assistance for rarely performed procedures or may require back-up in the event that hospital staff are not available to perform the procedures. A written physician order must be received by the Clinical Apheresis Services staff prior to the first procedure.

Carter BloodCare's therapeutic apheresis staff includes Registered Nurses and/or Hemapheresis Practitioners certified through the American Society of Clinical Pathologists, (ASCP) and apheresis technicians. All are trained in Basic Life Support/CPR (Cardiac Pulmonary Resuscitation).

All services listed below are provided by the Clinical Services department.

- Peripheral blood stem cell collection ( processing and storage provided by Carter BloodCare stem cell laboratory if needed)
- Therapeutic Apheresis Procedures
  - Plasmapheresis/Therapeutic Plasma Exchange (TPE)
  - Cell depletion or exchange
  - Red cell exchange
  - Leukoreduction
  - Platelet depletion
  - Photopheresis
  - Inpatient Therapeutic Phlebotomy
  - Granulocyte collection

## 13.2 Diseases which may be treated by Apheresis

### Plasmapheresis/Therapeutic Plasma Exchange (TPE)

- Bone marrow recipient receiving ABO incompatible marrow
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Eaton-Lambert Syndrome
- Goodpasture Syndrome
- Guillain-Barré Syndrome
- Hemolytic Uremic Syndrome
- Hyperviscosity Syndromes
- Multiple Myeloma (High Protein Load)
- Myasthenia Gravis
- Paraproteinemia (High Protein Load)
- Post -Transfusion Purpura
- Refsum Disease
- Thrombotic Thrombocytopenic Purpura
- Waldenstrom Macroglobulinemia
- Other situations, as determined after consultation with Carter BloodCare's medical staff

### Cell Depletion or Exchange

- Sickle Cell Anemia:
  - Pre-operative
  - Refractory pain crisis
  - Acute chest syndrome
  - Priapism
- Acute leukemia with severe leukocytosis
- Essential thrombocythemia
- Severe Malaria or Babesiosis
- Life-threatening hemolysis from incompatible blood transfusion

### Photopheresis

- Cutaneous T-cell Lymphoma, refractory to other therapies
- Mycosis Fungoides
- Sezary Syndrome
- Chronic Graft Versus Host Disease (hematopoietic stem cell transplant recipient)
- Cellular allograft rejection (lung or heart)
- Scleroderma (progressive systemic sclerosis), in some cases
- Rheumatoid Arthritis

### **13.3 Contract/Privileges**

**NOTE:** Due to regulatory considerations, a current, signed therapeutic apheresis services contract is required to initiate these services.

If a signed contract is not in place, emergency privileges must be established for professional staff performing the procedures. A signed contract will be initiated as soon as possible.

### **13.4 Emergency Privileges**

For emergency privileges several items must be completed prior to the procedure. A physician must agree to sponsor the professional staff. A facility administrator must give verbal approval for the procedure to be performed and provide basic billing information. To initiate emergency privileges, please contact Clinical Apheresis or a Carter BloodCare physician as soon as possible.

### **13.5 Granulocyte Orders**

To initiate a granulocyte order, please use pager number (817) 482-9466. Once your facility has been contacted for initiation of the order, a completed CAF495, Granulocyte Order/Release Form, must be filled out completely and faxed to Clinical Apheresis at 972-661-9409 before donors can be collected.

### **13.6 Forms**

- CAF495, Granulocyte Order/Release Form